SNIPRx^® is our proprietary, genome-wide, CRISPR-enabled discovery platform.

SNIPRx is our proprietary, genome-wide, CRISPR-based platform focused on genomic instability and DNA damage repair. It is a powerful synthetic lethal (SL) approach enabling novel target identification and differentiated patient selection insights.

Our SNIPRx platform begins with a genome-wide, CRISPR-based screening approach that utilizes proprietary isogenic cell lines that are identical except for a single genomic alteration, to identify novel SL gene pairs. Our systematic and comprehensive screening approach has been optimized to significantly reduce false negatives, providing the opportunity to identify a larger and more accurate set of SL interactions compared to other CRISPR-based screening approaches.

We have systematically analyzed genomic data from approximately 60,000 tumor samples and identified an initial set of clinically relevant genomic alterations, or tumor lesions, that are linked to genomic instability. These tumor lesions are present in approximately 30% of tumors and are largely mutually exclusive.

Each tumor lesion is screened using our SNIPRx platform to identify both previously-reported and unreported SL targets. With this approach, our SNIPRx screens have identified multiple potential targets, allowing us to prioritize and select targets to advance into drug discovery.

Once a SL product candidate is identified, we perform a further SNIPRx Targeted Expansion of Patient Populations (STEP²) screen. STEP² screens are used to identify additional genomic alterations that are SL with our product candidate, and help expand our target patient population by enabling us to potentially treat patients with tumors across multiple genomic alterations with the same product candidate.

By targeting patients with tumors that contain either the original lesion or any of the additional genomic alterations identified through our STEP² screens, we ensure the patients enrolling in our clinical trials are most likely to achieve clinical benefit from our product candidates.